Cite
Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD).
MLA
Weidinger, Stephan, et al. “Efficacy and Safety of Amlitelimab (an Anti-OX40 Ligand Antibody) in Patients with Moderate-to-Severe Atopic Dermatitis: 24-Week Results from a Phase 2b Trial (STREAM-AD).” British Journal of Dermatology, vol. 190, Feb. 2024, pp. ii24-ii26. EBSCOhost, https://doi.org/10.1093/bjd/ljad498.028.
APA
Weidinger, S., Blauvelt, A., Papp, K., Reich, A., Chih-Hung Lee, Worm, M., Lynde, C., Yoko Kataoka, Foley, P., Weber, C., Wanling Wong, Hurbin, F., Rynkiewicz, N., Yen, K., Xiaodan Wei, O’Malley, J. T., & Bernigaud, C. (2024). Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD). British Journal of Dermatology, 190, ii24-ii26. https://doi.org/10.1093/bjd/ljad498.028
Chicago
Weidinger, Stephan, Andrew Blauvelt, Kim Papp, Adam Reich, Chih-Hung Lee, Margitta Worm, Charles Lynde, et al. 2024. “Efficacy and Safety of Amlitelimab (an Anti-OX40 Ligand Antibody) in Patients with Moderate-to-Severe Atopic Dermatitis: 24-Week Results from a Phase 2b Trial (STREAM-AD).” British Journal of Dermatology 190 (February): ii24-ii26. doi:10.1093/bjd/ljad498.028.